Priya Shah, MD
Family Medicine · Dawsonville, GANPI 1154716405
Payments from drug & device makers
Across 319 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$690
- Amgen$533
- AstraZeneca$455
- Novo Nordisk$391
- Astellas Pharma US Inc$366
- plus $2K from 31 others
What the payments were for
- Consulting fees$1,20021%
- Food & beverage$4,63379%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 6 | $1,288 |
| AbbVie(2 entities) | 65 | $690 |
| Amgen(2 entities) | 36 | $533 |
| AstraZeneca | 34 | $455 |
| Novo Nordisk | 34 | $391 |
| Astellas Pharma US Inc | 22 | $366 |
| Amarin Pharma, Inc. | 13 | $266 |
| Lilly USA, LLC | 14 | $189 |
| Boehringer Ingelheim | 9 | $147 |
| GSK | 8 | $142 |
| Kowa Pharmaceuticals America, Inc. | 11 | $141 |
| Eisai Inc. | 6 | $100 |
| Scilex Pharmaceuticals Inc. | 4 | $93 |
| Teleflex LLC | 1 | $87 |
| Merck | 6 | $82 |
| Upsher-smith Laboratories LLC | 4 | $79 |
| Genentech USA, Inc. | 5 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Dexcom, Inc. | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 5 | $67 |
| Baxter Healthcare | 1 | $59 |
| Pfizer | 4 | $55 |
| Novartis | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Exact Sciences | 2 | $40 |
| Clarus Therapeutics Inc. | 3 | $39 |
| Phadia US Inc. | 2 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Bardy Diagnostics, Inc. | 1 | $23 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Bayer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$5,839 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 572 | $127,403 |
| OzempicSemaglutide | 70 | $112,162 |
| MounjaroTirzepatide | 63 | $75,214 |
| TrulicityDulaglutide | 32 | $60,117 |
| FarxigaDapagliflozin Propanediol | 36 | $38,671 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $18,972 |
| JardianceEmpagliflozin | 16 | $17,819 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $15,427 |
| LinzessLinaclotide | 13 | $15,025 |
| RybelsusSemaglutide | 15 | $14,009 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,619 |
| UbrelvyUbrogepant | 12 | $12,329 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,901 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,384 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $4,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Trelegy Ellipta | $142 | $140,022586 claims |
| Lilly USA, LLCMounjaro, Trulicity | $189 | $135,33295 claims |
| Novo NordiskOzempic, Rybelsus | $391 | $126,17085 claims |
| AstraZenecaFarxiga, Symbicort | $455 | $43,05549 claims |
| AbbVieLinzess, Ubrelvy | $690 | $27,35425 claims |
| Boehringer IngelheimJardiance | $147 | $17,81916 claims |
| MerckJanumet Xr | $82 | $15,42713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Dawsonville
- Larry AndersonDawsonville$774K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.